INVESTORS
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the effectiveness of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high dose levels to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The treatment is investigational and the company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers.
Exchange: NASDAQ
Symbol: DCTH